KR102937161B1 - 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 - Google Patents
당뇨병, 간염 및/또는 염증성 간질환의 치료 방법Info
- Publication number
- KR102937161B1 KR102937161B1 KR1020207022117A KR20207022117A KR102937161B1 KR 102937161 B1 KR102937161 B1 KR 102937161B1 KR 1020207022117 A KR1020207022117 A KR 1020207022117A KR 20207022117 A KR20207022117 A KR 20207022117A KR 102937161 B1 KR102937161 B1 KR 102937161B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- diabetes
- pharmaceutical composition
- composition according
- cys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020267006914A KR20260042289A (ko) | 2018-01-17 | 2019-01-17 | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862618332P | 2018-01-17 | 2018-01-17 | |
| US62/618,332 | 2018-01-17 | ||
| PCT/US2019/013934 WO2019143767A1 (en) | 2018-01-17 | 2019-01-17 | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267006914A Division KR20260042289A (ko) | 2018-01-17 | 2019-01-17 | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200110659A KR20200110659A (ko) | 2020-09-24 |
| KR102937161B1 true KR102937161B1 (ko) | 2026-03-10 |
Family
ID=65324621
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207022117A Active KR102937161B1 (ko) | 2018-01-17 | 2019-01-17 | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 |
| KR1020267006914A Pending KR20260042289A (ko) | 2018-01-17 | 2019-01-17 | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267006914A Pending KR20260042289A (ko) | 2018-01-17 | 2019-01-17 | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11866488B2 (https=) |
| EP (2) | EP4596042A3 (https=) |
| JP (2) | JP7486423B2 (https=) |
| KR (2) | KR102937161B1 (https=) |
| CN (2) | CN120267797A (https=) |
| AU (2) | AU2019209491B2 (https=) |
| BR (1) | BR112020014346A2 (https=) |
| CA (1) | CA3088661A1 (https=) |
| EA (1) | EA202091533A1 (https=) |
| ES (1) | ES3033317T3 (https=) |
| HR (1) | HRP20250727T1 (https=) |
| HU (1) | HUE072418T2 (https=) |
| IL (2) | IL316486A (https=) |
| MX (1) | MX2020007384A (https=) |
| PH (1) | PH12020551076A1 (https=) |
| PL (1) | PL3740282T3 (https=) |
| RS (1) | RS66918B1 (https=) |
| SG (1) | SG11202006421RA (https=) |
| SM (1) | SMT202500233T1 (https=) |
| WO (1) | WO2019143767A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020234718A1 (en) | 2019-03-13 | 2023-05-18 | Tearsolutions, Inc. | Compositions and methods for promoting islet viability and enhancing insulin secretion |
| EP3999531A1 (en) * | 2019-07-15 | 2022-05-25 | University of Connecticut | Metallothionein antibodies and their use |
| CN110551726B (zh) * | 2019-09-06 | 2021-04-09 | 上海市肺科医院 | 一种结核杆菌阿拉伯半乳聚糖适配子及其应用 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| KR102191405B1 (ko) * | 2020-09-15 | 2020-12-16 | 주식회사 에이스바이오메드 | 간 질환 예방 또는 치료용 조성물 |
| CN115317502B (zh) * | 2021-12-21 | 2023-07-07 | 青岛市市立医院 | 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用 |
| WO2025226837A1 (en) * | 2024-04-24 | 2025-10-30 | University Of Connecticut | Anti-bacterial metallothionein antibodies and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014172606A1 (en) * | 2013-04-19 | 2014-10-23 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20030007973A1 (en) | 2001-06-22 | 2003-01-09 | Lynes Michael A. | Methods and compositions for manipulation of the immune response using anti-metallothionein antibody |
| CA2658673A1 (en) | 2005-07-27 | 2008-02-01 | Gerald J. Prud'homme | Composition and method for prevention and treatment of type i and type ii diabetes |
| WO2011050052A2 (en) * | 2009-10-20 | 2011-04-28 | Georgia State University Research Foundation, Inc. | Protein agent for diabetes treatment and beta cell imaging |
| CA2813711A1 (en) | 2010-10-14 | 2012-04-19 | Immunahr Ab | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
| CA2840282C (en) | 2011-07-08 | 2018-11-13 | Universiteit Gent | Use of antagonists targeting metallothionein to treat intestinal inflammation |
| TR201402685A1 (tr) | 2014-03-06 | 2015-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vildagliptinin farmasotik formulasyonları. |
| EP3149049B1 (en) * | 2014-05-27 | 2022-10-26 | The University Of Queensland | Il-22 for use in treating metabolic disorders |
| TW201613949A (en) | 2014-08-07 | 2016-04-16 | Regulus Therapeutics Inc | Targeting microRNAs for metabolic disorders |
-
2019
- 2019-01-17 MX MX2020007384A patent/MX2020007384A/es unknown
- 2019-01-17 SG SG11202006421RA patent/SG11202006421RA/en unknown
- 2019-01-17 CA CA3088661A patent/CA3088661A1/en active Pending
- 2019-01-17 RS RS20250601A patent/RS66918B1/sr unknown
- 2019-01-17 KR KR1020207022117A patent/KR102937161B1/ko active Active
- 2019-01-17 JP JP2020537722A patent/JP7486423B2/ja active Active
- 2019-01-17 ES ES19703874T patent/ES3033317T3/es active Active
- 2019-01-17 WO PCT/US2019/013934 patent/WO2019143767A1/en not_active Ceased
- 2019-01-17 HU HUE19703874A patent/HUE072418T2/hu unknown
- 2019-01-17 IL IL316486A patent/IL316486A/en unknown
- 2019-01-17 EA EA202091533A patent/EA202091533A1/ru unknown
- 2019-01-17 SM SM20250233T patent/SMT202500233T1/it unknown
- 2019-01-17 CN CN202510512846.1A patent/CN120267797A/zh active Pending
- 2019-01-17 PL PL19703874.8T patent/PL3740282T3/pl unknown
- 2019-01-17 IL IL276097A patent/IL276097B2/en unknown
- 2019-01-17 US US16/961,327 patent/US11866488B2/en active Active
- 2019-01-17 AU AU2019209491A patent/AU2019209491B2/en active Active
- 2019-01-17 EP EP25158063.5A patent/EP4596042A3/en active Pending
- 2019-01-17 EP EP19703874.8A patent/EP3740282B1/en active Active
- 2019-01-17 KR KR1020267006914A patent/KR20260042289A/ko active Pending
- 2019-01-17 CN CN201980008316.6A patent/CN111801140B/zh active Active
- 2019-01-17 HR HRP20250727TT patent/HRP20250727T1/hr unknown
- 2019-01-17 BR BR112020014346-4A patent/BR112020014346A2/pt unknown
-
2020
- 2020-07-14 PH PH12020551076A patent/PH12020551076A1/en unknown
-
2022
- 2022-08-12 AU AU2022215285A patent/AU2022215285B2/en active Active
-
2023
- 2023-07-24 US US18/357,632 patent/US12583916B2/en active Active
- 2023-10-27 US US18/496,279 patent/US20240067710A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002422A patent/JP2024028454A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014172606A1 (en) * | 2013-04-19 | 2014-10-23 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102937161B1 (ko) | 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법 | |
| JP6633108B2 (ja) | 脂肪組織の集積を処置するための組成物および方法 | |
| US20260070996A1 (en) | Formulations for anti-insulin receptor antibody and uses thereof | |
| WO2017062693A1 (en) | Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies | |
| CN116059320A (zh) | 使用gdf11的治疗防止体重增加、提高葡萄糖耐量并减轻脂肪肝 | |
| TWI668010B (zh) | 使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病 | |
| HK40129169A (en) | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| KR20220034811A (ko) | 메탈로티오네인 항체 및 이의 용도 | |
| EA048509B1 (ru) | Способы лечения диабета, гепатита и/или воспалительного заболевания печени | |
| HK40040177A (en) | Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| HK40040177B (en) | Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| HK40002382B (en) | Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| F13 | Ip right granted in full following pre-grant review |
Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |